Table 3.
Disease severity, time from symptoms onset, percentage of positive samples to serological determination of SARS-CoV-2 antibodies and PRNT50 titers, subdivided by the studied groups.
| Groups | Samples evaluated for SARS-CoV-2 antibodies | Days from symptoms onset and serology (mean±SD) | Percentage of samples with positive assays results |
Samples tested for neutralization activity | Percentage of samples with neutralizing antibodies (PRNT50 ≥ 1:10) | ||||
|---|---|---|---|---|---|---|---|---|---|
| A | B | C | D | E | |||||
| Negative Healthy Workers (NHW) | 33/184 (17.9%) | - | 0% | 4.7% | 3.0% | 3.0% | 3.0% | - | - |
| Autoimmune Patients and Pregnant women (AI/Pr) | 21/184 (11.4%) | - | 0% | 0% | 0% | 0% | 0% | - | - |
| Asymptomatic / Paucisymptomatic SARS-CoV-2 positive Patients (Asympt/Pauci) | 8/184 (4.4%) | 54.6±22.5 | 100% | 100% | 100% | 100% | 100% | 6/8 (0.75%) | 6/6 (100%) |
| Moderate SARS-CoV-2 positive patients (Mod) | 56/184 (30.4%) | 19.5±13.7 | 76.8% | 75.0% | 69.6% | 83.6% | 73.2% | 33/56 (58.93%) | 29/33 (87.87%) |
| Severe SARS-CoV-2 positive patients (Sev) | 66/184 (35.9%) | 25.6±17.8 | 89.4% | 78.8% | 87.9% | 89.4% | 89.4% | 29/66 (43.93%) | 27/29 (93.10%) |
| Overall | 184 (100%) | 24.6±18.6 | 59.8% | 59.9% | 57.6% | 62.3% | 59.2% | 68/184 (36.95%) | 62/68 (91.18%) |
A = SARS-CoV-2 IgG, Abbott Laboratories; B = Elecsys Anti-SARS-CoV-2, Roche Diagnostic GmbH; C = Anti-SARS-CoV-2 IgG Ortho Clinical Diagnostics; D = Anti-SARS-CoV-2 Total Ortho Clinical Diagnostics; E= ELISA ENZY-WELL SARS-CoV-2 IgG Diesse Diagnostica Senese.